ECF vs. BBH, NQP, MUA, HRZN, MYN, TYG, HQL, KTF, MCI, and SOR
Should you be buying Ellsworth Growth and Income Fund stock or one of its competitors? The main competitors of Ellsworth Growth and Income Fund include VanEck Biotech ETF (BBH), Nuveen Pennsylvania Quality Municipal Income Fund (NQP), BlackRock MuniAssets Fund (MUA), Horizon Technology Finance (HRZN), BlackRock MuniYield New York Quality Fund (MYN), Tortoise Energy Infrastructure (TYG), Abrdn Life Sciences Investors (HQL), DWS Municipal Income Trust (KTF), Barings Corporate Investors (MCI), and Source Capital (SOR). These companies are all part of the "investment offices, not elsewhere classified" industry.
Ellsworth Growth and Income Fund (NYSE:ECF) and VanEck Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.
Ellsworth Growth and Income Fund has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, VanEck Biotech ETF has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
In the previous week, VanEck Biotech ETF had 2 more articles in the media than Ellsworth Growth and Income Fund. MarketBeat recorded 2 mentions for VanEck Biotech ETF and 0 mentions for Ellsworth Growth and Income Fund. VanEck Biotech ETF's average media sentiment score of 1.89 beat Ellsworth Growth and Income Fund's score of -0.86 indicating that VanEck Biotech ETF is being referred to more favorably in the news media.
35.9% of Ellsworth Growth and Income Fund shares are owned by institutional investors. Comparatively, 32.1% of VanEck Biotech ETF shares are owned by institutional investors. 0.5% of Ellsworth Growth and Income Fund shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Given VanEck Biotech ETF's higher probable upside, analysts plainly believe VanEck Biotech ETF is more favorable than Ellsworth Growth and Income Fund.
Ellsworth Growth and Income Fund pays an annual dividend of $0.52 per share and has a dividend yield of 6.4%. VanEck Biotech ETF pays an annual dividend of $0.71 per share and has a dividend yield of 0.4%.
VanEck Biotech ETF received 38 more outperform votes than Ellsworth Growth and Income Fund when rated by MarketBeat users.
Summary
VanEck Biotech ETF beats Ellsworth Growth and Income Fund on 5 of the 9 factors compared between the two stocks.
Get Ellsworth Growth and Income Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for ECF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ECF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ellsworth Growth and Income Fund Competitors List
Related Companies and Tools
